With updated Phase I/Ib data in hand, Arcus will launch a Phase III trial as it aims to compete with Merck, whose drug ...

The deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term ...

Arcus Biosciences (NYSE: RCUS) is setting the stage for a high-stakes Phase III showdown in kidney cancer, after early ...

Merck reports promising response rates for its ADC zilovertamab vedotin in relapsed DLBCL and KRAS inhibitor MK-1084 in solid ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD1 and VEGF, following ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary ...

Postoperative nivolumab added to standard-of-care adjuvant cisplatin radiotherapy “represents a potential new standard.” ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...

The first half of this year been riddled with market volatility and geopolitical tension. But 2025’s American Society of ...

Drugs that boost the body’s immune system to fight disease are showing promise in treating a variety of cancers in earlier ...

Bloomberg reported that Bristol-Myers Squibb Company (NYSE:BMY) and BioNTech SE (NASDAQ:BNTX) announced a strategic licensing ...